Topic Listing for Nektar Therapeutics

Accompanying Notes Integral Part Consolidated Financial Statements Accounting
Accounting Income Taxes Accounts Receivable Deferred Revenue
Accrued Expenses Accrued Obligations
Accrued Salary Paid Time Off Acknowledgement Rent Commencement
Acknowledgment Waiver Claims Adea Acquire Additional Companies Products Technologies Not Able Effectively
Additional Information Additional Information Merger Find
Additional Premises Address Principal Executive Offices Zip Code
Adea Adjustment Event Loss
Adjustment Provisions Adjustments
Administration Admission Liability
Adversely Affect Business Results Operations Financial Condition Advertising
Aerogen Aerogen Acquisition
Aerogen Safe Harbor Aggregate Unrecognized Share-based Compensation Expense
Aggregate Unrecognized Stock-based Compensation Expense Aggregated Option Exercises 2004 Values
Aggregated Option Exercises 2005 Values Agreed Accepted
Agreement Ajit Gill
Allowance Amed Xecutive Fficer Everance
Amended Restated Built-to-suit Lease Amended Stock Options
Amendment Amendment Agreement
Amendment Amended Restated Built-to-suit Lease Amendment Exclusive Research Development
Amendment Exclusive Research Development License Amendments
Amortization Other Intangible Assets Except Percentages Amphotericin Inhalation Powder Abip Prevention Pulmonary Fungal Infections
Amphotericin Inhalation Powder Abip Prevention Serious Pulmonary Infections Anda Act
Annual Meetings Anti-takeover Provisions Charter Documents Delaware Law Make Difficult
Appointment Principal Officers Approval 2000 Equity Incentive Plan Amended Restated
Approval Non-audit Services Architectural Drawings
Ariable Ash Ompensation Ase Alary
Asis Ayments Rom Lan Assignment Sublease Building
Assistance Questions Astrazeneca Party8221
Audit Audit Committee
Authority Authorized Shares Limits Awards
Available Information Backlog
Base Salary Basis Payments Plan
Baxter Healthcare Corp Bayer
Bayer Healthcare Bayer Healthcare Llc
Because Competition Highly Qualified Technical Personnel Intense Not Because Proprietary Product Candidates Early Stages Development High
Benchmarking Compensation Peer Companies Beneficial Owner Shares Registered Name Broker Bank
Beneficial Ownership Reporting Compliance Benefit Provision Income Taxes Except Percentages
Black-scholes Assumptions Blanket Policy
Board Directors Executive Compensation Board Directors Recommends Vote Each Named Nominee
Board Directors Recommends Vote Proposal Board Resignation Letter
Bonuses Variable Compensation Plan Bradford Operations
Bradforduk Operations Breaching Party
Brokers Build-to-suit Lease
Building Building Lease
Business Business Results Operations Financial Condition
Business Subject Changing Regulation Corporate Governance Public Disclosure California Labor Code Application Provision Providing Employee
Cannot Raise Additional Capital Financial Condition Suffer Capital Leases
Cash Equivalents Available-for-sale Investments Cash Equivalents Investments
Cash Equivalents Short-term Investments Marketable Securities Cashflow Activities
Ccounting Onsiderations Cdp 791 484 Programs
Cera Continuous Erythropoiesis Receptor Activator Program Certain Business Developments 2006
Certain Relationships Related Party Transactions Certain Relationships Related Transactions
Certain Relationships Related Transactions Director Independence Certain Transactions
Certificates Certifications
Challenge Change Control Severance Plan
Change Executive Management Board Directors Change Vote After Submitting Proxy
Changes Disagreements Accountants Accounting Financial Disclosure Changes Internal Control Over Financial Reporting
Changes Stockholders Equity Nine-months 2005 Chief Executive Officer Chairman Compensation
Choice Law Christopher Kuebler
Cimzia Certolizumab Pegol Cdp870 Program Cimzia Program
Cimzia Program Partnered Ucb Ciproflaxin Inhalation Powder Program
Ciproflaxin Inhalation Powder Program Partnered Bayer Civil Code 1542 Unknown Claims
Claims Claims Inquiries Appeals
Clinical Failure Remains High Prior Regulatory Approval Clinical Non-clinical Studies
Clinical Pipeline Clinical Studies
Clinical Trial Accruals Co-development License Co-promotion Agreement
Cobra Code Business Conduct Ethics
Collaboration Agreements Partners Contain Complex Commercial Terms Result Collaboration Agreements Pulmonary Pegylation Technology
Collaboration Agreements Pulmonary Products Collaborations Terminated 2004
Collaborations Terminated 2005 Collaborative Development License Agreement Pfizer Inc
Collaborative Partners Depend Obtain Regulatory Approvals Commercialize Partner Collaborative Partners Depend Obtain Regulatory Approvals Commercialize Products
Commencement Date Commitments Contingencies
Committees Common Stock Purchase Agreement
Comparison Cumulative Total Return Among Nektar Therapeutics Nasdaq Compensation Committee Report
Compensation Philosophy Compensation Plan Non-employee Directors
Compensation Program Objectives Philosophy Competing Product
Competition Competitors Develop Sell Better Drug Delivery Formulation Technologies
Complaining Party Compliance Laws
Compound Comprehensive Gain Loss
Comprehensive Income Loss Comprehensive Loss
Condemnation Condition
Condition Suffer Conditions Precedent
Conditions Sale Purchase Shares Conference Call Information
Confidentiality Agreement Consent Independent Registered Public Accounting Firm
Consideration Construction Improvements
Construction Progress Contact Joyce Strand 650 631-3138 Nektar Therapeutics Announces
Contents Contract Manufacturers
Contract Research Contract Research Revenue
Contractual Obligations Control Areas
Controls Procedures Conversion
Conversion Redemption Convertible Subordinated Notes
Convertible Subordinated Notes Debentures Copy Annual Report Securities Exchange Form 10-k 2006
Copy Annual Report Securities Exchange Form 10-k Amended Corporate Authority
Corporate Governance Corporate Seal
Cost Goods Sold Except Percentages Cost Goods Sold Gross Margin Except Percentages
Cost Idle Manufacturing Capacity Except Percentages Costs
Counterparts Counterparty
Counterparty Affiliate Covenants
Create Act Create Maintain High-value Partnerships
Creation Direct Financial Obligation Creation Direct Financial Obligation Off-balance Sheet Arrangement
Critical Accounting Policies Critical Accounting Policies Management Estimates
Critical Accounting Policies Managements Estimates Cure Period
Current Directors Nominated Reelecton Serve Until 2011 Annual Currently Involved Legal Proceedings Incur Substantial Litigation Costs
Damage Destruction Dated 2005
David Maris Bam Analyst David Steinberg Deutsche Bank Securities Analyst
Ddesa Deadline Shall Later Applicable Case Provided Pfizer
Debt Debtor
Deductibles Default
Deferred Compensation Definition Operating Expenses
Definitions Definity Peg
Dental Regeneration Products Departure Directors Certain Officers Election Appointment Compensatory
Departure Directors Certain Officers Election Appointment Compensatory Arrangements Departure Directors Principal Officers Election Appointment
Departure Principal Officers Depend Collaborative Partners Obtain Regulatory Approvals Commercialize Partner
Depend Contract Manufacturers Manufacture Exubera Inhaler Devices Failure Depend Contract Manufacturers Manufacture Exubera Inhalers Failure Sufficient
Depend Key Technical Management Personnel Advance Technology Loss Depend Parties Conduct Clinical Trials Proprietary Product Candidates
Depend Parties Conduct Proprietary Product Candidate Clinical Trials Depend Sole Exclusive Suppliers Pulmonary Inhaler Devices Bulk
Dependent Management Team Key Technical Personnel Loss Manager Deposit
Derivative Instruments Description
Description Base Salary Bonus Amounts Description Plan-based Awards
Description Select Development Programs Design Elements Compensation Program
Determination Operating Expenses Develop Own Proprietary Products
Develop Own Proprietary Products Utilizing Nektar Technologies Know-how Develop Portfolio Proprietary Product Candidates Leverage Pegylation Pulmonary
Development Agreement Development Plan Budget
Development Plan8221 Development Technology Commercially Reasonable Basis
Director Compensation Table Director Officer Indemnifications
Directors Directors Continuing Office Until 2009 Annual Meeting
Directors Continuing Office Until 2010 Annual Meeting Directors Executive Officers Corporate Governance
Directors Executive Officers Registrant Disclosure Controls Procedures
Discovery New Severe Side Effects Negative Efficacy Findings Discretionary Performance-based Incentive Compensation Policy
Dispute Distributor
Dividend Policy Dividends
Djustment Rovisions Djustments Pon Hanges Tock
Dministration Documents Incorporated Reference
Drives Business Strategy Nektar Therapeutics Drug Delivery Technologies Not Commercially Feasible Then Revenues
Drug Delivery Technologies Not Safe Then Regulatory Approval Drug Delivery Technologies Not Satisfy Certain Basic Feasibility
Drug Formulations Not Stable Then Able Develop Commercialize Drug Powder Packaging Filling
Drug Powder Product Manufacturing Duration Amendment Termination
Earthquakes Other Catastrophic Events Strike Business Harmed Earthquakes Other Catastrophic Events Strike Business Negatively Affected
Earthquakes Tornadoes Hurricanes Other Catastrophic Events Strike Business Ecitals
Ection Eneficial Wnership Eporting Ompliance Ederal Ncome Nformation
Eemployment Eetings Oard Irectors
Effect Certain Corporate Events Effect Certain Corporate Transactions
Effective Date Efinitions
Egal Onstruction Egulatory Atters
Eitf 07-03 Ektar Herapeutics
Ektar Herapeutics Hange Ontrol Everance Enefit Lan Eld Une 2005
Election Directors Eligibility
Eligibility Benefits Eligibility Participation Plan
Employee Agreement Employee Rehired Affiliate Prior Date Benefits Plan Scheduled
Employee Stock Purchase Plan Employees Consultants
Employment Agreement Continues Following Separation Date Continuing Obligations Employment Severance Change Control Agreements
Employment Transition Separation Release Agreement Enchmarking Ompensation Eer Ompanies
End Phase Meeting Enforce Rights
Enforcing Party Engineering Drawings
Entire Agreement Entry Material Definitive Agreement
Environment Environmental Claims
Environmental Matters Environmental Requirements
Enzon Product Development Collaboration Equity Awards
Equity Compensation Equity Compensation Plan Information
Equity Compensation Plans Not Approved Stockholders Equity Incentive Plan
Equity Interests Ermination Uspension Lan
Erms Ptions Erms Tock Onuses Urchases Estricted
Erquisites Ertain Elationships
Esign Lements Ompensation Rogram Estimates
Estoppel Certificates Estricted Tock Nit Greement
Estricted Tock Nit Rant Otice Estrictions Ransfer
Evaluation Disclosure Controls Procedures Events Default
Everance Hange Ontrol Enefits Exact Name Registrant Specified Charter
Exclusive Research Development Exclusivity
Execution Execution Delivery
Executive Compensation Executive Compensation Plan
Executive Officers Registrant Exhibits
Existing Publications Expect Continue Incur Substantial Losses Negative Cash Flow
Expect Continue Lose Money Next Few Not Reach Expect Stock Price Remain Volatile
Explanatory Exubera
Exubera Commercial Launch Early Stages Assurance Regarding Success Exubera Commercialization Readiness Costs
Exubera Commercialization Readiness Costs Except Percentages Exubera Commercialization Readiness Revenue
Exubera Commercialization Readiness Revenue Costs Exubera Commercialization Readiness Revenue Costs Except Percentages
Exubera Dry Powder Inhaled Insulin Exubera Fda Review Extension
Exubera Product Next-generation Inhaled Insulin Development Program Ngi Exubera-related Property Equipment
Fail Establish Future Successful Collaborative Relationships Then Financial Fail Establish Future Successful Collaborative Relationships Then Results
Fail Manage Executive Officer Transitions Business Suffer Fail Manage Growth Effectively Business Suffer
Fair Value Financial Instruments Fda Approved Products
Feasibility Studies Federal Income Tax Consequences Awards 2008 Plan
Federal Income Tax Information Ffect Ertain Orporate Vents
Ffective Ate Lan Ffer Etter Mployment Greements Amed Xecutive Fficers
Fin Final Accounting Lease
Financial Information Financial Statements Exhibits
Find Out Results Voting Annual Meeting Fixed Rent
Fluctuations Exubera Demand Negatively Impact Inhaler Contract Manufacturers Fluctuations Exubera Inhalation Powder Manufacturing Levels Negatively Impact
Following Issuance Lose Valuable Intellectual Property Protection Foreign Currency Risk
Form 10-q Form Selling Securityholder Notice Questionnaire
Former Name Address Changed Since Last Report Forward-looking Statements
Future Depends Proper Management Current Business Operations Associated Future Issuances Securities
Future Value Exubera Next-generation Inhaled Insulin Development Program Future Value Ngi Development Program Depends Successfully Securing
Gain Loss Debt Extinguishment Except Percentages Gain Termination Collaborative Agreements Net
Gain Termination Collaborative Agreements Net Except Percentages General
General Administrative Except Percentages General Administrative Expenses Except Percentages
General Business Overview General Indemnity
General Information General Release Not Extend Claims Creditor Know Suspect
General Required Identify Registered Broker-dealer Underwriter Prospectus Global Brand Team
Global Project Team Goodwill
Goodwill Other Intangible Assets Governing Law
Government Private Insurance Programs Not Pay Products They Government Private Insurance Programs Not Provide Reimbursement Partnered
Government Regulation Governmental Authority
Greement Group
Hares Ubject Lan Hari Sambasivam Merrill Lynch Analyst
Harmed Hat Mean Receive Proxy Card
Hat Quorum Requirement Hat Return Proxy Card Not Make Specific Choices
Hat Voting Haz Mat Documents
Hazardous Materials Hazardous Materials List
Held 2005 Held 2007
Hemophilia Program Hemophilia Programs Partnered Subsidiaries Baxter International
Hen Stockholder Proposals Due Next Annual Meeting Hief Xecutive Fficer Hairman Ompensation
Hief Xecutive Fficer Ompensation Hoice
Holders Record Holding Over
Householding Proxy Materials Howard Robin
Hoyoung Huh Nektar Therapeutics Phd Svp Business Dev Hoyoung Huh Nektar Therapeutics Phd Svp Business Development
Hsr Filing Http Wwwnektarcom
Ian Sanderson Cowen Analyst Icense Rants License Grants Bayer
Icu Antibiotic Advisory Board Ight Nterpret Lan Mendment Ermination
Ime Ayment Orm Enefit Impairment Goodwill Intangible Assets Other Long-lived
Impairment Goodwill Other Long-lived Assets Impairment Long Lived Assets Except Percentages
Impairment Long-lived Assets Impairment Long-lived Assets Contract Termination Costs
Impairment Long-lived Assets Except Percentages Implemented Certain Anti-takeover Measures Make Difficult Acquire Even
Implied Employment Contract Important Plan Information
Income Taxes Increasing Investment Development Commercialization New Products Prior Seeking
Increasing Investment Development Commercialization Proprietary Products Prior Seeking Incur Material Litigation Costs Adversely Affect Business Results
Incur Substantial Litigation Costs Liabilities Adversely Affect Business Indemnification
Indemnification Contract Manufacturers Indemnification Directors Executive Officers Other Employees Agents
Indemnification Procedures Indemnification Underwriters Initial Purchasers Securities
Indemnity Agreement Independence Board Directors
Independent Registered Public Accounting Firm Fees Services Index
Index Consolidated Financial Statements Index Exhibits
Industrial Road San Carlos California 94070 Information Board Directors
Infringement Suit Infringing Activities
Inhale Inhaled Amphotericin Abip
Inhaled Antibiotics Aerosolized Amikacin Adjunctive Treatment Pneumonias Mechanically Inhaled Antibiotics Program
Inhaled Antibiotics Treatment Hospital Pneumonia Inhaled Leuprolide Program
Inhaled Marinol Dronabinol Program Inherent Limitations Effectiveness Controls
Initial Phase Program Insider Participation
Insurance Insurers Primary Insurance
Interest Expense Except Percentages Interest Income Except Percentages
Interest Rate Market Risk Interest Rate Risk
Interest Rate Risk Convertible Subordinated Notes Interpretation
Interruption Introduction
Invalidity Action Inventories
Inventory Inventory Reserves
Investment Development Commercialization Proprietary Product Candidates Prior Seeking Investors Aware Industry-wide Risks Applicable Affect Revenues Results
Involved Legal Proceedings Incur Substantial Litigation Costs Liabilities Irwin Lerner
Iscellaneous Issuance 325 Convertible Subordinated Notes
Issuance Common Stock Issuer Purchases Equity Securities
Ithholding Bligations John Patton Phd
Joint Finance Committee Joint Steering Committee
Jon Lecroy Natexis Bleichroeder Analyst Joseph Krivulka
Jpt Jsc
Judgments Impacting Fixed Asset Capitalization Exubera Lack Progress Partnered Programs
Laims Nquiries Ppeals Landlords Default
Landlords Insurance Landlords Obligation Maintenance
Late Charge Launch Plan Budget Shared Territory
Lease Lease Premises
Lease Restoration Legal Construction
Legal Matters Legal Proceedings
Legal Rights Erisa Letter Agreement
Letters Credit Liabilities
License Manufacturing Supply Agreement License Manufacturing Supply Agreements Products Based Advanced Pegylation
License Manufacturing Supply Agreements Products Based Pegylation Technology Liens
Ligibility Ligibility Enefits
Limitation Landlord Liability Limitation Liability Exclusion Damages Disclaimer Warranty
Limitations Effectiveness Controls Liquidity Capital Resources
Litigation Litigation Audit Cooperation
Litigation Between Parties Litigation Settlement
Litigation Settlement Except Percentages Loans Officers
Loss Debt Extinguishment Except Percentages Loss Early Extinguishment Convertible Subordinated Notes
Loss Extinguishment Debt Except Percentages Loss Termination Capital Lease
Macugen Pegaptanib Sodium Injection Maintain Create High Value Partnerships
Management Managements Annual Report Internal Control Over Financial Reporting
Managements Report Internal Control Over Financial Reporting Manufacturing
Manufacturing Law Manufacturing Operations Those Contract Manufacturers Subject Governmental Regulatory
Manufacturing Supply Manufacturing Supply Agreement
Manufacturing Supply Agreement Contract Manufacturers Market Not Accept Products Based Technologies Then Revenues
Market Not Accept Products Using Drug Delivery Technologies Market Registrants Common Equity Related Stockholder Matters Issuer
Market Registrants Common Stock Related Stockholder Matters Material Breaches Agreement
Material Weakness Remediation Maximize Diabetes Opportunity
Meetings Meetings Board Directors
Memorandum Lease Mended Tock Ption Greement
Mendment Lan Tock Wards Merger
Michael Brown Michael Cass Sigma Value Analyst
Minimum Purchase Commitment Minimum Rental
Mircera Cera Continuous Erythropoiesis Receptor Activator Program Mircera Cera Continuous Erythropoietin Receptor Activator Program Partnered
Mount Enefit Mplied Mployment Ontract
Mployee Irector Ompensation Name Person Filing Proxy Statement Other Registrant
Nasdaq Pharmaceutical Index Nathan Sedati High Side Capital Management Analyst
Ndc Ndependence Oard Irectors
Nderstood Greed Nektar
Nektar Acquire Aerogen Broaden Pulmonary Technology Base Strengthen Nektar Advanced Pegylation Technology
Nektar Advanced Pegylation Technology Supercritical Fluid Nektar Advanced Pulmonary Delivery
Nektar Advanced Pulmonary Technology Nektar Agrees Not Materially Breach Obligations Remainder Page
Nektar Announces Common Stock Financing Nektar Announces Exercise Option Purchase Convertible Subordinated Notes
Nektar Appoints Howard Robin President Ceo Nektar Letterhead
Nektar Party8221 Nektar Pegylation Platform
Nektar Plan Administrator Nektar Proprietary Product Development Programs
Nektar Proprietary Products Programs Nektar Pulmonary Technology
Nektar Safe Harbor Nektar Supercritical Fluid Technology
Nektar Technology Patents Nektar Technology Within Lpp Patents
Nektar Therapeutics Nektar Therapeutics 201 Industrial Road San Carlos 94070
Nektar Therapeutics Appoints New Chief Financial Officer Nektar Therapeutics Letterhead
Nektar Variable Compensation Plan Net Loss Per Share
Neulasta Pegfilgrastim Nevan Elam Nektar Therapeutics Svp Head Pulmonary Business
New Patentable Licensed Know-how New Potential Accounting Pronouncements Impact Future Financial Position
Nformation Egarding Oard Irectors Ommittees Nktr-061 Inhaled Amikacin
Nktr-061 Inhaled Amikacin Partnered Bayer Nktr-102 Peg-irinotecan
Nktr-118 Oral Peg-naloxol Nominating Corporate Governance Committee
Non-clinical Studies Non-disparagement
Non-employee Directors Stock Option Plan Non-gaap Financial Measures
Non-officer Equity Incentive Plan Non-terminated Country8221
Not Able Manufacture Breath-actuated Dry Powder Inhaler Device Not Able Manufacture Dry Powder Inhaler Device Commercially
Not Able Manufacture Products Accordance Cgmp Commercially Feasible Not Able Manufacture Products Commercially Feasible Quantities Costs
Not Able Manufacture Products Using Nektar Advanced Pegylation Not Able Manufacture Supply Sufficient Quantities Exubera Inhalation
Not Able Manufacture Supply Sufficient Quantities Powder Formulated Not Able Obtain Intellectual Property Licenses Related Development
Not Generate Sufficient Cash Flow Through Increased Revenue Not Generate Sufficient Cash Flow Through Increased Revenues
Not Successful Conducting Human Clinical Trials Products Developed Not Successful Designing Developing New Next Generation Pulmonary
Not Successful Developing Next Generation Exubera Pulmonary Inhaler Not Successful Developing Next Generation Pulmonary Insulin Inhaler
Notice Notice Annual Meeting Stockholders Held 2006
Notices Notwithstanding Provision Purposes Applying Pfizer Shall Deemed Met
Novartis Pharma Ntroduction
Nuisance Number 0-24006
Nventions Now Atents Obligations
Obligations Harm Development Commercialization Plans Ode Usiness Onduct Thics
Off Balance Sheet Arrangements Off-balance Sheet Arrangements
Office Equipment Officers
Offices Okay Thank
Ole Rganization Ompensation Ommittee Etting Xecutive Ominating Orporate Overnance Ommittee
Ommercialization Commercialization Plan Budget Shared Territory Ompensation Hilosophy
Ompensation Irectors Ompensation Ommittee Eport
Ompensation Rogram Bjectives Ompensation Xecutive Fficers
Oncology Advisory Committee Onuses Ariable Ompensation
Operating Leases Operations Associated Expenses
Operations Financial Condition Operations Financial Condition Negatively Affected
Operations Growth Operations Not Achieve Sustain Profitability Future
Option Either Party Shall Propose Makes Such Proposal Option Exercises Stock Vested
Options Options Extend Term
Orange Book Listable Patent Organization
Organization Basis Presentation Organization Ccc Shall Consist Members Each Party Appoint
Organization Compensation Committee Organization Compensation Committee Interlocks Insider Participation
Ostabolin-c Inhalation Powder Program Other
Other Benefits Other Current Assets
Other Debt Other Events
Other Events Required Disclosure Other Important Information
Other Income Expense Except Percentages Other Income Expense Net Except Percentages
Other Information Other Intangible Assets
Other Matters Other Plan Information
Other Securities Corporation Other Select Partnered Products
Outline Manufacturing Supply Agreement Ovenants Ompany
Overlandlord Overlandlord8217s Consent
Overnance Overview
Overview Nektar Technologies Overview Selected Proprietary Product Development Programs
Owner Ownership Inventions
Parking Part Other Information
Participating Affiliates Parties
Partner Pharmaceutical Biotechnology Companies Partner Product Development Programs
Partnered Product Development Programs Partners Depend Obtain Regulatory Approvals Commercialize Partnered Products
Partners Not Able Manufacture Products Quantities Costs Commercially Partners Not Obtain Regulatory Approval Product Candidates Timely
Partners Not Obtain Regulatory Approval Products Timely Basis Partnership
Partnership Pfizer Exubera Party Claims
Past Revenue Therefore Not Necessarily Indicative Future Patent Exclusivity List
Patent Prosecution Maintenance Patent Working Group
Patents Proprietary Rights Paying Proxy Solicitation
Payment Payment Operating Expenses
Payment Schedule Payments
Peg Cdp 860 Program Peg Cdp 870 Peg-anti-tnf Alpha Antibody Fragment Program
Peg-intron Peginterferon Alfa-2b Pegasys Peginterferon Alfa-2a
Pegylation Pulmonary Drug Development Pending Future Lawsuits
Pending Patent Applications Not Issue Deemed Invalid Following Pending Patent Applications Not Issue Following Issuance Deemed
Performance Affiliates Performance Measurement Comparison
Permitted Perquisites
Personal Property Pfizer Concludes Continuing Countries Referred Cannot Justified Due
Pfizer Directly Through Parties Pfizer Inc
Pfizer Inc Not Able Manufacture Fill Bulk Insulin Pfizer Inhale Collaboration Agreement
Pfizer Not Able Fill Bulk Drug Powders Exubera Pfizer Party Providing Such Proposed Disclosure Inhale Review
Pfizer Termination Agreement Settlement Pfizer Unable Manufacture Deliver Bulk Insulin Powder Processing
Pfizers Slower Anticipated Progress Commercializing Exubera Material Impact Phase Shall Meaning Assigned
Plan Plan Amendment Termination
Pledge Security Deposit Policy
Post-termination Control Agreements Potential Payments Termination Change Control
Pproval Olicies Rocedures Pre-approval Policies Procedures
Pre-clinical Clinical Proprietary Product Development Programs Pre-clinical Clinical Testing Trials Delayed Unsuccessful Then Experience
Pre-clinical Proprietary Products Preclinical Clinical Proprietary Product Development Programs
Preclinical Testing Clinical Trials Conducted Partners Delayed Unsuccessful Preclinical Testing Clinical Trials Those Collaborative Partners Delayed
Preferred Stock Prices Common Stock Senior Convertible Debt Expected Remain
Principal Accountants Fees Services Principal Accounting Fees Services
Principles Consolidation Principles Consolidation Estimates
Procedure Review Press Releases Other Publications Proceeding Relief
Product Liability Lawsuits Brought Against Incur Substantial Liabilities Product Profit Loss
Product Sales Royalties Product Sales Royalty Revenue
Products Delayed Unsuccessful Products Not Cost Effective Then Government Private Insurance
Products Using Nektar Pulmonary Technology Not Provide Consistent Products Using Pulmonary Technology Not Provide Consistent Doses
Proforma Effects Applying Sfas 123 Prior Periods Prohibition Compliance Indemnity
Prohibition Period Project Shall Meaning Assigned
Properties Property Equipment
Property Management Fee Proprietary Products
Proprietary Products Strategic Advisory Board Proration
Proration Termination Prosecution
Prudent Actions Plan Fiduciaries Ption Rovisions
Publication Pulmonary Advisory Board
Pulmonary Advisory Committee Purchase Nektar Facility
Purchase Sale Common Stock Delivery Shares Purpose
Quantitative Qualitative Disclosures Market Risk Question Answer Session
Questionnaire Quiet Enjoyment
Quity Wards Quorum Voting
Ratification Selection Independent Auditors Ratification Selection Independent Registered Public Accounting Firm
Real Estate Capital Leases Real Property Taxes
Receive Information Plan Benefits Receiving Materials
Receiving Party Recent Accounting Pronouncements
Recent Developments Recently Appointed New President Chief Executive Officer Failure
Recitals Reclassification
Reclassifications Redemption
Redemption Interest Inhale 201 Partnership Reemployment
Regional Business Unit Registrants Telephone Number Including Area Code
Registrants Telephone Number Including Area Code 650 631-3100 Regulation Disclosure
Regulatory Compliance Related Party Transactions
Release Claims Release Include Known Unknown Claims
Releasees Rely Trade Secret Protection Other Unpatented Proprietary Rights
Remain Volatile Remainder Page Intentionally Blank Signature Follows
Remainder Page Intentionally Blank-signature Follows Remediation Material Weakness
Remedies Cumulative Remedies Tenants Default
Rental Report Audit Committee Board Directors
Report Independent Registered Public Accounting Firm Representations Warranties Parent Merger Sub
Repricing Required Obtain Intellectual Property Licenses Parties Risk Not
Research Development Research Development Efforts Delayed Unsuccessful Then Experience Delay
Research Development Except Percentages Research Development Expense
Research Development Expenses Except Percentages Reservation Compensation
Reserve Account Reserved Shares
Resignation Restatement
Restoration Improvements Restricted Information
Restricted Stock Unit Summary Restricted Stock Units
Restrictions Transfer Restructuring
Restructurings Retirement Certain Convertible Subordinated Notes
Retirement Plan Return Property Proprietary Information Agreement
Revenue Except Percentages Revenue Geography
Revenue Historically Depended Collaboration Agreements Causing Significant Fluctuation Revenue Historically Depends Collaboration Agreements Therefore Fluctuates Significantly
Revenue Recognition Revenue Results Operations Depend Commercial Success Exubera
Revenue Results Operations Depend Sales Pfizer Revenue Results Operations Depend Successful Commercial Launch Exubera
Rganization Ompensation Ommittee Rganization Ompensation Ommittee Nterlocks Nsider Articipation
Rich Silver Lehman Brothers Analyst Right Entry
Right Interpret Plan Amendment Termination Right Make Alterations
Rights Landlord Effect Landlords Consent Rincipal Ccountant Ees Ervices
Risk Factors Robert Chess
Roceeds Rom Tock Rovisions Tock Wards Ther Ptions
Roy Whitfield Royalties
Royalties Royalty Territory Sab 108
Safety Agreement Sale Landlords Interest
Sales Unregistered Securities San Carlos Calif 2009
San Carlos California 94070 Schedule
Scientific Advisory Group Scope
Script Conference Call Follows Securities Authorized Issuance Equity Compensation Plans
Securities Exchange Act 1934 Securities Registered Pursuant Act
Securities Registered Pursuant Act Common Stock 00001 Par Security Agreement Pfizer Inc
Security Measures Security Ownership Certain Beneficial Owners Management Related Stockholder
Securityholders Diluted Price Securities Decrease Exercise Outstanding Stock Securityholders Diluted Prices Securities Decrease Exercise Outstanding Stock
Segment Information Segment Reporting
Segment Significant Customer Geographic Information Separation Benefits
Separation Consideration Separation Date
Separation Date Release Separation Date Transition Period
Separation General Release Agreement Series Convertible Preferred Stock
Series Preferred Stock Settlement Agreement General Release
Severability Severance Benefit Plan
Severance Benefits Severance Benefits Provided Named Executive Officers Former Employees
Severance Change Control Benefits Sfas 123r
Sfas 157 Sfas 159
Share-based Compensation Shared Territory Pre-launch Costs Profit-sharing
Shares Stock Shipping Handling Costs
Signature Page Amendment Signature Page Follows
Signatures Signed Within After Separation Date
Significant Collaborative Research Development Agreements Significant Collaborative Research Development Product Agreements
Significant Competition Technology Platforms Partnered Proprietary Product Candidates Significant Competition Technology Platforms Partnered Proprietary Products Product
Significant Concentrations Significant Partnered Product Development Programs
Significantly Harm Business Signs
Site Plan Shall Meaning Assigned Solicitation Employees
Solvay Pharmaceuticals Inc Somavert Pegvisomant
Source Shares Stock Subject Plan Unissued Reacquired Bought Special Meetings
Specific Benefits 2008 Equity Incentive Plan Spraygel Peg-hydrogel Program
Statement Cash Flows Data Statement Erisa Rights
Stock Issued Non-employees Stock Option Grants 2004
Stock Option Grants 2005 Stock Option Grants Exercises
Stock Option Plans Stock Option Summary
Stock Options Issued Non-employees Stock Options Restricted Units
Stock Subject Non-officer Plan Stock-based Compensation
Stockholder Communications Board Directors Stockholder Proposals Due Next Annual Meeting
Stockholder Record Shares Registered Name Stockholders
Stockholders Equity Stockholders Meetings
Strategic Advisory Board Strategic Alliance-enzon
Strategy Strategy Develop Proprietary Product Candidates Prior Seeking Partnership
Subcontracting Permitted Subject Ccc Members Reporting Party Changed Time Sole
Subject Party Subleased Premises
Sublicensee Submission Matters Vote Security Holders
Subordination Mortgage Subsequent Events
Subsidiaries Subsidiaries Nektar Therapeutics
Subtenant Subtenant Hazmat Operations
Subtenant Representation Warranty Subtenant8217s Obligations
Subtenant8217s Work Successors Assigns
Such Time Pfizer Notifies Inhale Not Intend Accordance Summary Details Plan Share Options
Summary Rsu Award Activity Summary Stock Option Activity
Summary Stock Options Supplemental Agreement Alliance Pharmaceutical Corp
Surrender Surrender Plan
Survival Survival Rights
Susan Wang Table Contents
Tatement Risa Ights Taxes
Technologies Cannot Integrated Successfully Bring Products Market Then Technologies Not Commercially Feasible Then Negatively Impact Revenues
Technologies Not Satisfy Certain Basic Feasibility Requirements Such Technology Competition
Technology Platforms Tenant Fixtures Personal Property
Tenant Improvement Loans Tenant Work Plans
Tenants Insurance Tenants Obligation Maintenance
Tenants Remedies Tenure Duties Officers
Term Termination
Termination Agreement Contract Manufacturers Termination Agreement Mutual Release
Termination Astrazeneca Material Breach Termination Contract Manufacturing Agreement Exubera Resulted Significant Expenses
Termination Date Termination Exubera Inhalermanufacturing Supply Agreement
Termination Material Definitive Agreement Termination Nektar Material Breach
Termination Notice Termination Partnership Pfizer Likely Reduce Revenue Significantly 2008
Termination Pfizer Agreements Result Significant Expenses Charges Termination Pfizer Agreements Significantly Reduce Future Revenue
Terms Agreement Terms Awards
Terre Haute Indiana Manufacturing Facility Testing
Ther Enefits Ther Lan Nformation
Tim Warner Nektar Therapeutics Svp Investor Relations Corporate Time Accelerated Restricted Stock Award Plan Tarsap
Time Payment Form Benefit Title Alterations
Tobramycin Inhalation Powder Program Tobramycin Inhalation Powder Tip Program
Tobramycin Inhalation Powder Tip Program Partnered Novartis Pharma Tobramycin Inhaled Powder Program
Tock Ption Greement Tock Ptions
Tock Ptions Estricted Nits Ther Quity Wards Tock Ptions Ther Quity Wards
Tock Ubject Lan Tockholder Ommunications Oard Irectors
Trademarks Transaction
Transaction Bonus Transfer Premiums
Transfers Record Shares Stock Corporation Shall Only Books Transition Agreement
Transitional Employment Types Awards
Uah Udit Ommittee
Ummary Unable Establish Maintain Partnerships Commercially Attractive Terms Business
Unconditional Purchase Obligations Underground Tanks
Undisclosed Peg Product United States
Unlikely Derive Revenue Exubera Not Secure New Marketing Unrecognized Share-based Compensation Expense
Unregistered Sale Equity Securities Proceeds Unregistered Sales Equity Securities
Unregistered Sales Equity Securities Proceeds Unvested Shares Issued Plan
Unvested Stock Options Issued Option Plans Uration Mendment Ermination
Urpose Urposes
Variable Compensation Plan Vested Options
Voluntary Execution Agreement Legal Counsel Vote
Vote Annual Meeting Vote Required Approval 2008 Equity Incentive Plan
Votes Votes Counted
Votes Needed Approve Each Proposal Voting Securities Owned Corporation
Waiver Waiver Jury Trial
Waiver Subrogation Waivers Modifications
Warrants What Householding Affect
What Mean Receive Proxy Card What Quorum Requirement
What Return Proxy Card Not Make Specific Choices What Voting
Work Letter Workers Compensation
Workforce Reduction Writing Required
Xecution Xercise
Xhibit 104 Xhibit 1053
Xhibit 1054 Xhibit 1055
Zelos Therapeutics Inc 
Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki